ArticleBlood2015
Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 85 citations in OpenAlex.
- Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology.British journal of cancer · 2026Review
- Emerging Roles, Mechanisms, and Therapeutic Potential of Thyroid Hormones in Neurodegenerative Diseases: A Review.Brain sciences · 2026Review
- Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination.Blood advances · 2025Article
- Relationship Between Thyroid Dysfunction and Ovarian Cancer.Biomolecules · 2025Review
- Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.Current topics in medicinal chemistry · 2025Review
- PCK2, a SASP-Associated Gene, Serves as an Independent Prognostic Indicator in Diffuse Large B-Cell Lymphoma.Journal of inflammation research · 2025Article
- Editorial: Thyroid hormone actions in cancer, volume II.Frontiers in endocrinology · 2025Article
- PKCα Activation via the Thyroid Hormone Membrane Receptor Is Key to Thyroid Cancer Growth.International journal of molecular sciences · 2024Article
- Advances in biology, diagnosis and treatment of DLBCL.Annals of hematology · 2024Review
- Progesterone modulates cell growth via integrin αvβ3-dependent pathway in progesterone receptor-negative MDA-MB-231 cells.Heliyon · 2024Article
- Hyperthyroidism and the risk of non-thyroid cancer: a Danish register-based long-term follow-up study.European thyroid journal · 2024Article
- Protective effect of higher free thyroxine levels within the reference range on biliary tract cancer risk: a multivariable mendelian randomization and mediation analysis.Frontiers in endocrinology · 2024Article
- The Interplay between Integrins and Immune Cells as a Regulator in Cancer Immunology.International journal of molecular sciences · 2023Review
- Editorial: Thyroid hormone actions in cancer.Frontiers in endocrinology · 2023Article
- What is thyroid function in your just-diagnosed cancer patient?Frontiers in endocrinology · 2023Article
- Structure-Based Discovery of a Novel Class of Small-Molecule Pure Antagonists of Integrin αVβ3.Journal of chemical information and modeling · 2022Article
- Scaffold-mediated switching of lymphoma metabolism in culture.Cancer & metabolism · 2022Article
- Three-dimensional models: a novel approach for lymphoma research.Journal of cancer research and clinical oncology · 2022Review
- The interplay of thyroid hormones and the immune system - where we stand and why we need to know about it.European journal of endocrinology · 2022Review
- Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.Cancer discovery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
The interaction of lymphoid tumor cells with components of the extracellular matrix via integrin αvβ3 allows tumor survival and growth. This integrin was demonstrated to be the membrane receptor for thyroid hormones (THs) in several tissues. We found that THs, acting as soluble integrin αvβ3 ligands, activated growth-related signaling pathways in T-cell lymphomas (TCLs). Specifically, TH-activated αvβ3 integrin signaling promoted TCL proliferation and angiogenesis, in part, via the upregulation of vascular endothelial growth factor (VEGF). Consequently, genetic or pharmacologic inhibition of integrin αvβ3 decreased VEGF production and induced TCL cell death in vitro and in human xenograft models. In sum, we show that integrin αvβ3 transduces prosurvival signals into TCL nuclei, suggesting a novel mechanism for the endocrine modulation of TCL pathophysiology. Targeting this mechanism could constitute an effective and potentially low-toxicity chemotherapy-free treatment of TCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.